Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patien...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2020-03, Vol.111 (3), p.401-408 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 408 |
|---|---|
| container_issue | 3 |
| container_start_page | 401 |
| container_title | International journal of hematology |
| container_volume | 111 |
| creator | Yamaguchi, Hiroki Takezako, Naoki Ohashi, Kazuteru Oba, Koji Kumagai, Takashi Kozai, Yasuji Wakita, Hisashi Yamamoto, Koh Fujita, Akira Igarashi, Tadahiko Yoshida, Chikashi Ohyashiki, Kazuma Okamoto, Shinichiro Sakamoto, Junichi Sakamaki, Hisashi Inokuchi, Koiti |
| description | Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patients could achieve treatment-free remission (TFR) after stopping the administration of dasatinib using dasatinib as frontline treatment. Treatment-naïve chronic phase CML cases were treated with dasatinib as frontline treatment. Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years. Ten patients (38.5%) achieved DMR maintenance after 12 months. Recurrence was confirmed in 16 patients, and the median recurrence-free survival time was 5.1 months. The cumulative DMR rates at six and 12 months after restarting treatment were 84.6% and 100%, respectively. The results of this study demonstrated that the DMR maintenance rate after 12 months was 38.5%, which was not significantly different from previous TKI stop trials. The 2-year dasatinib administration period after reaching DMR did not contribute to improve TFR rates. These results suggest that the type of TKI is not associated with better TFR rates. |
| doi_str_mv | 10.1007/s12185-019-02801-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2332082988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2332082988</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-f189d22867d164a71e3bcdbfe595b3a7976becb1bddb92b32812c1fa537520a73</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhBVggS2zYGPwTxwk7NEBBDLBoWUd2fMO4JHZqO6qmr8RL4s5Mi8SCla1zv3uurw9Czxl9zShVbxLjrJGEspZQ3lBGbh6gFWtqSYRS1UO0oi2XRCpGT9CTlC4pZYpW6jE6EaxpKynECv2-iKDzBD6TIQLgCJNLyQWP9ZAh4sHFlMnoPGCrk87OO4PzXQ92Hs9FLNeEr13e4n4bg3c9nnYwBmfxCMuvYqlvybyF-_q81Qne7qX35Btcn-PzvNgdDsNe-6J9Dnj9dXOUz2JY5qfo0aDHBM-O5yn68fHDxfoT2Xw_-7x-tyG9aNuyR1nOct7UyrK60oqBML01A8hWGqFVq2oDvWHGWtNyI3jDeM8GLYWSnGolTtGrg-8cw9UCKXflT3oYR-0hLKnjQnDa8LZpCvryH_QyLNGX1xVK1hUtSbBC8QPVx5BShKGbo5t03HWMdrdRdocouxJlt4-yuylNL47Wi5nA3rfcZVcAcQBSKfmfEP_O_o_tHzEirHY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356403771</pqid></control><display><type>article</type><title>Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Yamaguchi, Hiroki ; Takezako, Naoki ; Ohashi, Kazuteru ; Oba, Koji ; Kumagai, Takashi ; Kozai, Yasuji ; Wakita, Hisashi ; Yamamoto, Koh ; Fujita, Akira ; Igarashi, Tadahiko ; Yoshida, Chikashi ; Ohyashiki, Kazuma ; Okamoto, Shinichiro ; Sakamoto, Junichi ; Sakamaki, Hisashi ; Inokuchi, Koiti</creator><creatorcontrib>Yamaguchi, Hiroki ; Takezako, Naoki ; Ohashi, Kazuteru ; Oba, Koji ; Kumagai, Takashi ; Kozai, Yasuji ; Wakita, Hisashi ; Yamamoto, Koh ; Fujita, Akira ; Igarashi, Tadahiko ; Yoshida, Chikashi ; Ohyashiki, Kazuma ; Okamoto, Shinichiro ; Sakamoto, Junichi ; Sakamaki, Hisashi ; Inokuchi, Koiti</creatorcontrib><description>Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patients could achieve treatment-free remission (TFR) after stopping the administration of dasatinib using dasatinib as frontline treatment. Treatment-naïve chronic phase CML cases were treated with dasatinib as frontline treatment. Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years. Ten patients (38.5%) achieved DMR maintenance after 12 months. Recurrence was confirmed in 16 patients, and the median recurrence-free survival time was 5.1 months. The cumulative DMR rates at six and 12 months after restarting treatment were 84.6% and 100%, respectively. The results of this study demonstrated that the DMR maintenance rate after 12 months was 38.5%, which was not significantly different from previous TKI stop trials. The 2-year dasatinib administration period after reaching DMR did not contribute to improve TFR rates. These results suggest that the type of TKI is not associated with better TFR rates.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-019-02801-z</identifier><identifier>PMID: 31894533</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Chronic myeloid leukemia ; Clinical trials ; Dasatinib - administration & dosage ; Dasatinib - therapeutic use ; Female ; Hematology ; Humans ; Kinases ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Maintenance ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Myeloid leukemia ; Oncology ; Original Article ; Prognosis ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Protein-Tyrosine Kinases ; Remission ; Remission (Medicine) ; Remission Induction ; Restarting ; Survival Rate ; Time Factors ; Tyrosine</subject><ispartof>International journal of hematology, 2020-03, Vol.111 (3), p.401-408</ispartof><rights>Japanese Society of Hematology 2020</rights><rights>International Journal of Hematology is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-f189d22867d164a71e3bcdbfe595b3a7976becb1bddb92b32812c1fa537520a73</citedby><cites>FETCH-LOGICAL-c399t-f189d22867d164a71e3bcdbfe595b3a7976becb1bddb92b32812c1fa537520a73</cites><orcidid>0000-0002-0571-7495</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-019-02801-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-019-02801-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31894533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Takezako, Naoki</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Oba, Koji</creatorcontrib><creatorcontrib>Kumagai, Takashi</creatorcontrib><creatorcontrib>Kozai, Yasuji</creatorcontrib><creatorcontrib>Wakita, Hisashi</creatorcontrib><creatorcontrib>Yamamoto, Koh</creatorcontrib><creatorcontrib>Fujita, Akira</creatorcontrib><creatorcontrib>Igarashi, Tadahiko</creatorcontrib><creatorcontrib>Yoshida, Chikashi</creatorcontrib><creatorcontrib>Ohyashiki, Kazuma</creatorcontrib><creatorcontrib>Okamoto, Shinichiro</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Inokuchi, Koiti</creatorcontrib><title>Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patients could achieve treatment-free remission (TFR) after stopping the administration of dasatinib using dasatinib as frontline treatment. Treatment-naïve chronic phase CML cases were treated with dasatinib as frontline treatment. Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years. Ten patients (38.5%) achieved DMR maintenance after 12 months. Recurrence was confirmed in 16 patients, and the median recurrence-free survival time was 5.1 months. The cumulative DMR rates at six and 12 months after restarting treatment were 84.6% and 100%, respectively. The results of this study demonstrated that the DMR maintenance rate after 12 months was 38.5%, which was not significantly different from previous TKI stop trials. The 2-year dasatinib administration period after reaching DMR did not contribute to improve TFR rates. These results suggest that the type of TKI is not associated with better TFR rates.</description><subject>Chronic myeloid leukemia</subject><subject>Clinical trials</subject><subject>Dasatinib - administration & dosage</subject><subject>Dasatinib - therapeutic use</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Maintenance</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Protein-Tyrosine Kinases</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Restarting</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Tyrosine</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhS0EokPhBVggS2zYGPwTxwk7NEBBDLBoWUd2fMO4JHZqO6qmr8RL4s5Mi8SCla1zv3uurw9Czxl9zShVbxLjrJGEspZQ3lBGbh6gFWtqSYRS1UO0oi2XRCpGT9CTlC4pZYpW6jE6EaxpKynECv2-iKDzBD6TIQLgCJNLyQWP9ZAh4sHFlMnoPGCrk87OO4PzXQ92Hs9FLNeEr13e4n4bg3c9nnYwBmfxCMuvYqlvybyF-_q81Qne7qX35Btcn-PzvNgdDsNe-6J9Dnj9dXOUz2JY5qfo0aDHBM-O5yn68fHDxfoT2Xw_-7x-tyG9aNuyR1nOct7UyrK60oqBML01A8hWGqFVq2oDvWHGWtNyI3jDeM8GLYWSnGolTtGrg-8cw9UCKXflT3oYR-0hLKnjQnDa8LZpCvryH_QyLNGX1xVK1hUtSbBC8QPVx5BShKGbo5t03HWMdrdRdocouxJlt4-yuylNL47Wi5nA3rfcZVcAcQBSKfmfEP_O_o_tHzEirHY</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Yamaguchi, Hiroki</creator><creator>Takezako, Naoki</creator><creator>Ohashi, Kazuteru</creator><creator>Oba, Koji</creator><creator>Kumagai, Takashi</creator><creator>Kozai, Yasuji</creator><creator>Wakita, Hisashi</creator><creator>Yamamoto, Koh</creator><creator>Fujita, Akira</creator><creator>Igarashi, Tadahiko</creator><creator>Yoshida, Chikashi</creator><creator>Ohyashiki, Kazuma</creator><creator>Okamoto, Shinichiro</creator><creator>Sakamoto, Junichi</creator><creator>Sakamaki, Hisashi</creator><creator>Inokuchi, Koiti</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0571-7495</orcidid></search><sort><creationdate>20200301</creationdate><title>Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group</title><author>Yamaguchi, Hiroki ; Takezako, Naoki ; Ohashi, Kazuteru ; Oba, Koji ; Kumagai, Takashi ; Kozai, Yasuji ; Wakita, Hisashi ; Yamamoto, Koh ; Fujita, Akira ; Igarashi, Tadahiko ; Yoshida, Chikashi ; Ohyashiki, Kazuma ; Okamoto, Shinichiro ; Sakamoto, Junichi ; Sakamaki, Hisashi ; Inokuchi, Koiti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-f189d22867d164a71e3bcdbfe595b3a7976becb1bddb92b32812c1fa537520a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chronic myeloid leukemia</topic><topic>Clinical trials</topic><topic>Dasatinib - administration & dosage</topic><topic>Dasatinib - therapeutic use</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Maintenance</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Protein-Tyrosine Kinases</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Restarting</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Takezako, Naoki</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Oba, Koji</creatorcontrib><creatorcontrib>Kumagai, Takashi</creatorcontrib><creatorcontrib>Kozai, Yasuji</creatorcontrib><creatorcontrib>Wakita, Hisashi</creatorcontrib><creatorcontrib>Yamamoto, Koh</creatorcontrib><creatorcontrib>Fujita, Akira</creatorcontrib><creatorcontrib>Igarashi, Tadahiko</creatorcontrib><creatorcontrib>Yoshida, Chikashi</creatorcontrib><creatorcontrib>Ohyashiki, Kazuma</creatorcontrib><creatorcontrib>Okamoto, Shinichiro</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Inokuchi, Koiti</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Hiroki</au><au>Takezako, Naoki</au><au>Ohashi, Kazuteru</au><au>Oba, Koji</au><au>Kumagai, Takashi</au><au>Kozai, Yasuji</au><au>Wakita, Hisashi</au><au>Yamamoto, Koh</au><au>Fujita, Akira</au><au>Igarashi, Tadahiko</au><au>Yoshida, Chikashi</au><au>Ohyashiki, Kazuma</au><au>Okamoto, Shinichiro</au><au>Sakamoto, Junichi</au><au>Sakamaki, Hisashi</au><au>Inokuchi, Koiti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>111</volume><issue>3</issue><spage>401</spage><epage>408</epage><pages>401-408</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patients could achieve treatment-free remission (TFR) after stopping the administration of dasatinib using dasatinib as frontline treatment. Treatment-naïve chronic phase CML cases were treated with dasatinib as frontline treatment. Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years. Ten patients (38.5%) achieved DMR maintenance after 12 months. Recurrence was confirmed in 16 patients, and the median recurrence-free survival time was 5.1 months. The cumulative DMR rates at six and 12 months after restarting treatment were 84.6% and 100%, respectively. The results of this study demonstrated that the DMR maintenance rate after 12 months was 38.5%, which was not significantly different from previous TKI stop trials. The 2-year dasatinib administration period after reaching DMR did not contribute to improve TFR rates. These results suggest that the type of TKI is not associated with better TFR rates.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31894533</pmid><doi>10.1007/s12185-019-02801-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0571-7495</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2020-03, Vol.111 (3), p.401-408 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2332082988 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Chronic myeloid leukemia Clinical trials Dasatinib - administration & dosage Dasatinib - therapeutic use Female Hematology Humans Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Maintenance Male Medical prognosis Medicine Medicine & Public Health Myeloid leukemia Oncology Original Article Prognosis Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Protein-Tyrosine Kinases Remission Remission (Medicine) Remission Induction Restarting Survival Rate Time Factors Tyrosine |
| title | Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A14%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment-free%20remission%20after%20first-line%20dasatinib%20treatment%20in%20patients%20with%20chronic%20myeloid%20leukemia%20in%20the%20chronic%20phase:%20the%20D-NewS%20Study%20of%20the%20Kanto%20CML%20Study%20Group&rft.jtitle=International%20journal%20of%20hematology&rft.au=Yamaguchi,%20Hiroki&rft.date=2020-03-01&rft.volume=111&rft.issue=3&rft.spage=401&rft.epage=408&rft.pages=401-408&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-019-02801-z&rft_dat=%3Cproquest_cross%3E2332082988%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2356403771&rft_id=info:pmid/31894533&rfr_iscdi=true |